uniQure (QURE) Reports Phase I/II Trial Results from AAV5-Based Gene Therapy in Sanfilippo B Syndrome
Tweet Send to a Friend
uniQure N.V. (Nasdaq: QURE) announced the topline results of one-year follow-up data from a Phase I/II clinical trial conducted by ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
